VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 410 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2013. The put-call ratio across all filers is 0.62 and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $17,033,000 | -70.2% | 732,908 | -73.4% | 0.05% | -72.6% |
Q4 2017 | $57,221,000 | +364.1% | 2,753,652 | +286.4% | 0.19% | +313.3% |
Q2 2017 | $12,329,000 | +57.6% | 712,674 | +32.3% | 0.04% | +50.0% |
Q4 2016 | $7,823,000 | +121.2% | 538,803 | +206.8% | 0.03% | +100.0% |
Q2 2016 | $3,536,000 | +1132.1% | 175,594 | +1507.1% | 0.02% | +1400.0% |
Q1 2016 | $287,000 | -98.4% | 10,926 | -89.5% | 0.00% | -98.9% |
Q3 2015 | $18,496,000 | -71.1% | 103,660 | -64.1% | 0.10% | -68.2% |
Q2 2015 | $64,076,000 | -34.2% | 288,598 | -41.2% | 0.30% | -37.7% |
Q1 2015 | $97,415,000 | +643.3% | 490,657 | +435.7% | 0.48% | +557.5% |
Q4 2014 | $13,106,000 | -86.7% | 91,584 | -88.3% | 0.07% | -83.6% |
Q2 2014 | $98,680,000 | +121.5% | 782,433 | +131.5% | 0.44% | +86.2% |
Q1 2014 | $44,552,000 | +5597.2% | 337,951 | +4973.6% | 0.24% | +5875.0% |
Q4 2013 | $782,000 | -97.0% | 6,661 | -97.4% | 0.00% | -97.6% |
Q3 2013 | $26,267,000 | – | 251,766 | – | 0.17% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |